{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:54:04Z","timestamp":1760205244228,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.gore.2024.101374","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T15:53:52Z","timestamp":1712073232000},"page":"101374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9705-0642","authenticated-orcid":false,"given":"Shannon M.","family":"Glynn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-2241","authenticated-orcid":false,"given":"Anna L.","family":"Beavis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"46","key":"10.1016\/j.gore.2024.101374_b0005","article-title":"Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series","volume":"31","author":"Calo","year":"2023","journal-title":"Gynecol Oncol Rep."},{"issue":"5","key":"10.1016\/j.gore.2024.101374_b0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"3","key":"10.1016\/j.gore.2024.101374_b0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2021.06.033","article-title":"Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes","volume":"162","author":"Gadducci","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"166","key":"10.1016\/j.gore.2024.101374_b0020","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0090-8258(22)01325-7","article-title":"Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099)","volume":"1","author":"Hinchcliff","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2024.101374_b0025","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7150\/jca.41296","article-title":"Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes","volume":"11","author":"Jiang","year":"2020","journal-title":"J Cancer."},{"issue":"3","key":"10.1016\/j.gore.2024.101374_b0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ygyno.2021.07.005","article-title":"ARID1A mutation\/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer","volume":"162","author":"Kuroda","year":"2021","journal-title":"Gynecol Oncol."},{"issue":"1","key":"10.1016\/j.gore.2024.101374_b0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13048-020-00751-3","article-title":"Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report","volume":"13","author":"Lin","year":"2020","journal-title":"J Ovarian Res."},{"issue":"8","key":"10.1016\/j.gore.2024.101374_b0040","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1158\/1535-7163.MCT-10-0169","article-title":"VEGF is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary","volume":"9","author":"Mabuchi","year":"2010","journal-title":"Mol Cancer Ther."},{"issue":"26","key":"10.1016\/j.gore.2024.101374_b0045","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer","volume":"38","author":"Makker","year":"2020","journal-title":"JCO."},{"issue":"7","key":"10.1016\/j.gore.2024.101374_b0050","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2024.101374_b0055","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med."},{"issue":"8","key":"10.1016\/j.gore.2024.101374_b0060","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1136\/ijgc-2022-003430","article-title":"Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series","volume":"32","author":"Sia","year":"2022","journal-title":"Int J Gynecol Cancer."},{"key":"10.1016\/j.gore.2024.101374_b0065","doi-asserted-by":"crossref","unstructured":"Tan DSP, Choi CH, Ngoi N, Sun H, Heong V, Ow SGW, et al. A multicenter phase II randomized trial of durvalumab (D) versus physician\u2019s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3). JCO. 2022 Jun;40(16_suppl):5565\u20135565.","DOI":"10.1200\/JCO.2022.40.16_suppl.5565"},{"issue":"15","key":"10.1016\/j.gore.2024.101374_b0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/OTT.S362267","article-title":"Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report","volume":"2","author":"Zhao","year":"2022","journal-title":"Onco Targets Ther."},{"issue":"1","key":"10.1016\/j.gore.2024.101374_b0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924000535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924000535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:54:03Z","timestamp":1718340843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578924000535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":15,"alternative-id":["S2352578924000535"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2024.101374","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2024.101374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101374"}}